34278 Federal Register / Vol. 87, No. 108 / Monday, June 6, 2022 / Notices 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Santanu Banerjee, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2106, 

Bethesda, MD 20892, (301) 435–5947, 

banerjees5@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: May 31, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12043 Filed 6–3–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer Institute 

Council of Research Advocates. 

The meeting will be held as a virtual 

meeting and is open to the public. 

Individuals who plan to view the virtual 

meeting and need special assistance or 

other reasonable accommodations to 

view the meeting, should notify the 

Contact Person listed below in advance 

of the meeting. The meeting will be 

videocast and can be accessed from the 

NIH Videocasting and Podcasting 

website (http://videocast.nih.gov). 

Name of Committee: National Cancer 

Institute Council of Research Advocates. 

Date: June 29, 2022. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: Welcome and Chairman’s 

Remarks, NCI Updates, Legislative Update, 

and Acting Director’s Update. 

Place: National Institutes of Health, 9000 

Rockville Pike, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Amy Williams, NCI Office 

of Advocacy Relations, National Cancer 

Institute, NIH, 31 Center Drive, Building 31, 

Room 10A28, Bethesda, MD 20892, (301) 

496–9723, williaam@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: NCRA: http:// 

deainfo.nci.nih.gov/advisory/ncra/ncra.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS). 

Dated: May 31, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12042 Filed 6–3–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Biomedical 

Imaging and Bioengineering; Notice of 

Proposed Reorganization 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Institute of 

Biomedical Imaging and Bioengineering 

(NIBIB) will host a public hearing to 

enable public discussion of the 

Institute’s proposal to establish the 

Center for Biomedical Imaging and 

Technology Acceleration (bETA). The 

proposed reorganization aims to 

accelerate the development, validation, 

and dissemination of high-impact 

biomedical technologies to address 

urgent national and global health needs. 

DATES: The public hearing will take 

place on June 29, 2022, at 2 p.m. using 

NIBIB’s social media accounts. Any 

interested party may also file written 

comments by sending an email to 

NIBIBorgchange@nih.gov prior or 

during the scheduled public hearing. 

The statement should include the 

individual’s name, and when 

applicable, professional affiliation. 

ADDRESSES: The following email address 

has been established for comments on 

the reorganization: NIBIBorgchange@

nih.gov. The social media platforms that 

will be used and monitored during this 

hearing are: 

• Twitter: @NIBIBgov 

• Facebook: https://www.facebook.com/ 

nibibgov/ 

FOR FURTHER INFORMATION CONTACT: Eva 

Kakoza, Management Analyst, National 

Institute of Biomedical Imaging and 

Bioengineering, NIH, (301) 402–4584, 

NIBIBorgchange@nih.gov. 

SUPPLEMENTARY INFORMATION: Pursuant 

to the NIH Reform Act of 2006 (42 

U.S.C. Sec.281 (d)(4)), NIBIB will have 

a public hearing to discuss the proposed 

reorganization plans. This 

announcement and the public forum 

serve as that notice. More information 

can be found at https://

www.nibib.nih.gov/about-nibib/ 

proposed-org-changes. 

Jason M. Ford, 

Executive Officer, National Institute of 

Biomedical Imaging and Biomedical 

Engineering, National Institutes of Health. 

[FR Doc. 2022–12073 Filed 6–3–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; RFA DK21–012 

SBIR Review. 

Date: June 29, 2022. 

Time: 1:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: NIDDK, NIH, 6707 Democracy Blvd., 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Ann A. Jerkins, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7119, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, 301–594–2242, 

jerkinsa@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 108 / Monday, June 6, 2022 / Notices 34279 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: May 31, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12005 Filed 6–3–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Special 

Emphasis Panel; PAR 22–102 & PAR 22–103: 

Investigational New Drug (IND)-Enabling and 

Early-Stage Development of Medications to 

Treat Alcohol Use Disorder and AlcoholAssociated Organ Damage. 

Date: June 17, 2022. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Alcohol Abuse and 

Alcoholism, 6700B Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Ranga Srinivas, Ph.D., 

Chief, Extramural Project Review Branch, 

National Institute on Alcohol Abuse and 

Alcoholism, National Institutes of Health, 

6700 B Rockledge Drive, Room 2114, 

Bethesda, MD 20892, (301) 451–2067, 

srinivar@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards, National 

Institutes of Health, HHS) 

Dated: May 31, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12041 Filed 6–3–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Cancer 

Therapeutics and Drug Development. 

Date: June 30–July 1, 2022. 

Time: 10:00 a.m. to 9:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jonathan Arias, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5170, 

MSC 7840, Bethesda, MD 20892, (301) 435– 

2406, ariasj@csr.nih.gov. 

Name of Committee: Genes, Genomes, and 

Genetics Integrated Review Group 

Maximizing Investigators’ Research Award A 

Study Section. 

Date: July 5–6, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Mollie Kim Manier, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–0510, mollie.manier@

nih.gov. 

Name of Committee: Digestive, Kidney and 

Urological Systems, Integrated Review 

Group, Pathobiology of Kidney Disease, 

Study Section. 

Date: July 6–7, 2022. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Atul Sahai, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2188, 

MSC 7818, Bethesda, MD 20892, 301–435– 

1198, sahaia@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Member 

Conflict: Molecular and Cellular Sciences 

and Technologies. 

Date: July 6, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Raj K Krishnaraju, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6190, 

Bethesda, MD 20892, 301–435–1047, 

kkrishna@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Fellowships: 

Oncology. 

Date: July 6–7, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Nywana Sizemore, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6189, 

MSC 7804, Bethesda, MD 20892, 301–408– 

9916, sizemoren@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Small 

Business: Computational, Modeling and 

Biodata Management. 

Date: July 6, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Marie-Jose Belanger, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm 6188, MSC 

7804 Bethesda, MD 20892, (301) 435–1267, 

belangerm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Cellular and 

Molecular Aspects of the Blood-Brain Barrier 

and Neurovascular System and Therapeutic 

Strategies. 

Date: July 7, 2022. 

Time: 9:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jacek Topczewski, Ph.D., 

Scientific Review Officer, Center for 


lotter on DSK11XQN23PROD with NOTICES1